ACT Onco® + Report

PATIENT		
Name: 劉宸嘉		Patient ID: 48580672
Date of Birth: Oct 05, 2000		Gender: Male
Diagnosis: Malignant peripheral nerve sheath tumor		
ORDERING PHYSICIAN		
Name: 張延驊醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11125765L	Collection site: Kindey	Type: FFPE tissue
Date received: Jul 22, 2022	Lab ID: AA-22-04244	D/ID: NA

ABOUT ACTOnco®+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) (≤ 15 nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

SUMMARY FOR ACTIONABLE VARIANTS

VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
NF1 Q83*	Everolimus, Selumetinib, Trametinib	Afatinib, Erlotinib, Gefitinib, Lapatinib, Cetuximab, Trastuzumab, Vemurafenib
IL6 Amplification	-	Erlotinib, Gefitinib, Trastuzumab

Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criterial for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

ACT Onco® + Report

TESTING RESULTS

VARIANT(S) WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
NF1	Q83*	96.1%

- Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr16	*PALB2*	Heterozygous deletion	1
Chr7	*EGFR*	Amplification	6¥
Chr4	*KDR, KIT, PDGFRA*	Amplification	7¥
Chr7	*IL6*	Amplification	9
Chr7	*CARD11*	Amplification	11

¥ Increased gene copy number was observed.

- Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

- Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	6.3 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

Note:
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 77% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at ≥ 7.5 mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is < 30%.

ACT Onco® + Report

THERAPEUTIC IMPLICATIONS

TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
Level 3B		
NF1 Q83*	Selumetinib	**sensitive**
Level 4		
NF1 Q83*	Everolimus, Trametinib	**sensitive**
NF1 Q83*	Afatinib, Erlotinib, Gefitinib, Lapatinib, Cetuximab, Trastuzumab, Vemurafenib	**resistant**
IL6 Amplification	Erlotinib, Gefitinib, Trastuzumab	**resistant**

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
1	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
2	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
3A	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
3B	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
4	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

ACT Onco® + Report

IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

- Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

HORMONAL THERAPIES

Genomic Alterations	Therapies	Effect	Level of Evidence	Cancer Type
NF1 Q83*	Tamoxifen	**Less sensitive**	Clinical	Breast cancer

OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

Note:
Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

ACT Onco® + Report

VARIANT INTERPRETATION

NF1 Q83*

Biological Impact

The neurofibromin 1 (NF1) gene encodes a GTPase activating protein (GAP) which is an important negative regulator of the Ras cellular proliferation pathways[1][2][3][4]. Besides, NF1 also physically interacts with the N-terminal domain of focal adhesion kinase (FAK) and involves in the regulation of cell adhesion, growth, and other pathways[5][6]. NF1 is considered a classical haploinsufficient tumor suppressor gene with loss of one allele through inherited or acquired mutation may lead to reduced protein expression and is insufficient to execute normal cellular functions contributing to tumor development[7][8][9][10][11]. NF1 syndrome is a germline condition resulting in a predisposition to several types of cancer such as neurofibromas, melanoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, hematological malignancies[12][13][14]. Meanwhile, sporadic NF1 mutations have been observed in multiple cancer types[15], including myelodysplastic syndromes, melanomas, colon cancer[16], glioblastomas[17], lung cancer[18], ovarian cancer, and breast cancer[12].

Q83* mutation results in a premature truncation of the NF1 protein at amino acid 83 (UniProtKB). This mutation is predicted to lead to a loss of NF1 function, despite not having characterized in the literature.

Therapeutic and prognostic relevance

In April 2020, the U.S. FDA has approved selumetinib for pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). A phase II trial (NCT02664935, NLMT) demonstrated that selumetinib in combination with docetaxel resulted in a confirmed ORR of 28.5% (4/14), durable clinical benefit (DCB) rate of 50% (7/14), and mPFS of 5.3 months in lung adenocarcinoma patients harboring NF1 loss[19]. NF1 loss has been determined as an inclusion criterion for the trials evaluating selumetinib efficacies in lung cancer (NCT02664935) and NF1-associated tumors (NCT03326388).

NF1 depletion has been associated with drug resistance to RAF and EGFR inhibitors, tamoxifen, and retinoic acid[15][20]. For example, loss of NF1 was identified in patients with lung adenocarcinomas or colorectal cancer who presented resistance to anti-EGFR treatment, including erlotinib, gefitinib, afatinib, and cetuximab, respectively[21][22][23]. Loss of NF1 in patients with BRAF-mutated melanomas was also suggested conferring resistance to BRAF inhibitors[24][25][26][27].

Notably, preclinical studies further revealed that the addition of a MEK inhibitor could restore the sensitivity to erlotinib[21]. Also, in a liquid biopsy-based ctDNA profiling study of HER2-positive metastatic gastric cancer, NF1 loss (either induced by mutation or deletion) was suggested as a novel mechanism contributes to trastuzumab resistance. The cell-based study also showed that the trastuzumab and lapatinib resistance could be overcome with a combination of HER2 and MEK/ERK inhibitors[28]. A case study had reported that MEK inhibitor, trametinib, was effective in a treatment-refractory neurofibromatosis type I-associated glioblastoma[29]. Various preclinical data had also supported the activity of MEK and mTOR inhibitors in NF1-deficient tumors[30][31][32][33][34][35]. In an NGS-based study, patients harboring mutations in the mTOR pathway, including mTOR, TSC1, TSC2, NF1, PIK3CA, and PIK3CG responded to everolimus[36].

CARD11 Amplification

Biological Impact

CARD11 (caspase recruitment domain 11) gene encodes a cytoplasmic scaffold protein of the CARD11/BCL10/MALT1 (CBM) complex which plays essential roles in regulating apoptosis and NF-κB activation in response to upstream stimuli[37][38]. CARD11 gain-of-function mutations are frequently detected in human diffuse large B-cell lymphoma (DLBCL)[39]and cutaneous squamous cell carcinoma[40]. Moreover, CARD11 gene amplification has been observed in a significant proportion of DLBCL[41]. Biochemical assays revealed that enforced expression of CARD11/BCL10/MALT1 is essential for transformation of B-cell and survival of DLBCL cell[42].

Therapeutic and prognostic relevance
Retrospective studies have shown that high CARD11 expression or CARD11 gene amplification was associated with poor survival in diffuse large B cell lymphoma (DLBCL)[43][41].

EGFR Amplification
Biological Impact
The EGFR gene encodes for the Epidermal Growth Factor Receptor, a receptor tyrosine kinase which binds to its ligands, including Epidermal Growth Factor (EGF) and Transforming Growth Factor-alpha (TGF-alpha), activates downstream signaling pathways, including the canonical oncogenic MAPK and PI3K/AKT/mTOR signaling cascades[44]. Increased EGFR activity by mutations and/or amplification of the EGFR gene has been described in a wide range of cancers, such as lung, brain, colorectal and head and neck cancer[45]. Mutations in the kinase domain of EGFR are commonly observed in non-small cell lung cancer (NSCLC), resulting in a constitutively activated form of the receptor[46]. On the other hand, in the brain and colorectal cancers, the most prevalent EGFR alteration is copy number amplification that results in receptor overexpression[47].

Therapeutic and prognostic relevance
There is accumulated clinical evidence suggested that patients with MDM2/MDM4 amplification or EGFR aberrations exhibited poor clinical outcome and demonstrated a significantly increased rate of tumor growth (hyper-progression) after receiving immune checkpoint (PD-1/PD-L1) inhibitors therapies[48](Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376).

Increased EGFR copy number is associated with tumor response to panitumumab, an EGFR-targeted antibody, in colorectal cancer patients, based on data from a phase III study[49]. A recent Phase II trial of cetuximab (another approved anti-EGFR antibody) oxaliplatin/leucovorin/5-fluorouracil therapy in first-line setting also demonstrated an association between higher EGFR copy number and better overall survival in gastric cancer patients[50]. The addition of cetuximab to chemotherapy reduced the risk of death by 44% for advanced squamous non–small cell lung cancer (NSCLC) patients with EGFR-amplified tumor, according to clinical trial findings presented at the 2015 World Conference on Lung Cancer. Preclinical data of gastric cancer (GC)-derived xenograft also showed that EGFR amplification or overexpression is associated with response to cetuximab[51]. Besides, a phase III study of necitumumab showed squamous cell lung cancer patients with EGFR amplification had improved overall survival (14.8 versus 7.6 months, p = 0.033) (NCT00981058)[52].

Increased EGFR copy number has been shown to be associated with better response and survival in gefitinib or erlotinib treatment for NSCLC[53][54][55][56][57][58], esophageal cancer[59], and mucinous urethral adenocarcinoma[60]. Concurrent amplification of EGFR and ERBB2 is associated with response to afatinib in patients with trastuzumab-refractory esophagogastric cancer[61]. However, dacomitinib has been reported with a limited single-agent activity in recurrent glioblastoma with EGFR amplification in a phase II trial[62]. EGFR amplification has been determined as an inclusion criterion for the trials evaluating erlotinib, afatinib, and osimertinib efficacy in PDAC with co-expressing EGFR and c-Met (NCT03213626), glioblastoma (NCT03732352), urothelial tract carcinoma (NCT02780687), and brain cancer (NCT02423525).

IL6 Amplification
Biological Impact
The Interleukin 6 (IL6) gene encodes a key cytokine produced by various cell types including monocytes, macrophages, fibroblasts, keratinocytes, endothelial cells, B cells, T cells, and also several tumor cells during infection and inflammation. It is a pleiotropic cytokine that regulates the immune response, tissue regeneration, and promoting tumor growth and survival[63][64][65][66]. In cancers, IL6 is implicated in inflammation to malignant transformation by activating the NF-κB pathway, and the induction of an epithelial-mesenchymal transition (EMT)[67].

Therapeutic and prognostic relevance

Preclinical studies showed that IL6 is sufficient to modify the sensitivity of EGFR mutant non-small cell lung cancer (NSCLC) cell line to erlotinib treatment[68]. Inhibition of IL6 signaling by metformin can potentiate gefitinib-induced antitumor activity[69].

A preclinical study showed that increased expression of the cytokines IL6 was associated with trastuzumab resistance in HER2+ breast cancer[70].

Amplification of IL6 was associated with shortened survival in glioblastoma patients[71].

KDR Amplification

Biological Impact

KDR (kinase domain receptor), also known as VEGFR2 or Flk-1, is a tyrosine kinase receptor for the vascular endothelial growth factor (VEGF) and involves in angiogenesis pathway[72]. Binding of VEGF to KDR results in activation of phospholipase C (PLC-gamma) and downstream signaling via protein kinase C (PKC) and RAF/MEK/ERK[73]. Mutations of KDR are rare in tumors, and alterations of KDR activity typically occur via KDR amplification and subsequent overexpression[74][75].

Therapeutic and prognostic relevance

To date, there are four VEGF inhibitors (sorafenib, sunitinib, pazopanib, bevacizumab)[76][77]and one VEGFR2 inhibitor cabozantinib[78]that are FDA-approved for the treatment of cancers.

Notably, a case report showed that an angiosarcoma patient with concurrent KDR and FLT4 amplification developed a progressive disease when treated with sorafenib, but experienced a potent antitumor response and achieved clinically stable disease for 6 months after receiving pazopanib therapy[79]. Besides, an angiosarcoma patient with upregulated VEGFR2 responded to sunitinib treatment[80].

VEGFR2 inhibitors like apatinib and vandetanib are in early clinical phase trial[81][82][83].

The increased copy number of KIT or KDR significantly correlated with a worse 5-year breast cancer-specific survival (BCSS) in triple-negative breast cancer (TNBC) patients[84].

KDR amplification and/or mutation has been selected as an inclusion criteria for the trial examining cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) (NCT04631744) and sunitinib in malignant solid tumors (NCT03297606).

KIT Amplification

Biological Impact

KIT is a proto-oncogene that encodes a type 3 transmembrane receptor tyrosine kinase. Activation of KIT through dimerization and autophosphorylation upon binding by its ligand results in increased intracellular PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT signaling pathways to promote cell proliferation and survival[85]. KIT activating mutations are frequently found in 80 - 90% of gastrointestinal stromal tumors (GISTs) which distributed over multiple exons with different frequencies (exons 11 (66.1%), exon 9 (13%), exon 13 (1.2%), and exon 17 (0.6%))[86][87].

Therapeutic and prognostic relevance

The NCCN guidelines for cutaneous melanoma suggested KIT hotspots mutations which located in exon 11 and exon 13 (eg. W557, V559, L576P, K642E) have a high level of sensitivity to KIT inhibitors (imatinib, sunitinib, nilotinib)[88][89][90]. However, KIT exon 17 mutations (eg. D816H) and KIT amplification appeared to be resistant to KIT inhibitors in patients

with melanoma.

The efficacies of several U.S. FDA-approved KIT-targeting tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, regorafenib, and ripretinib are strongly dependent on the location of the activating KIT mutations[91][92][93][94][95][96][97][98][99][100]. Patients with GIST harboring KIT exon 9 mutations showed intermediate sensitivity to imatinib and had better relapse-free survival and overall survival (OS) compared with patients carrying KIT exon 11 mutations[92].

Ponatinib and dasatinib yielded a disease control rate and partial control rate of 67% and 32%, respectively, in GIST patients harboring KIT exon 11 mutations (DOI: 10.1200/jco.2015.33.15_suppl.10535, 10.1200/jco.2011.29.15 _suppl.10006). Results from a Phase II trial involving melanoma showed 38.5% response rate to nilotinib in patients harboring KIT exon 11 mutations[101].

Both KIT and PDGFRA overexpression were associated with high tumor grade, high proliferation index, and poor outcome in patients with the serous type of ovarian carcinoma[102].

The newly developing agents such as avapritinib (BLU-285) and investigational AZD3229 all showed the potential to be better inhibitors for clinically relevant KIT/PDGFRA mutations in GIST[103].

KIT mutations have been determined as an inclusion criterion for the trials evaluating avapritinib, sunitinib, nilotinib, ponatinib, regorafenib, and ripretinib efficacies in advanced or metastatic solid tumors, advanced or metastatic GIST, advanced systemic mastocytosis (AdvSM), and relapsed or refractory myeloid malignancies (NCT04771520, NCT03465722, NCT02693535, NCT02561988, NCT01028222, NCT01099514, NCT03171389, NCT02272998, NCT02501551, and NCT02571036).

A phase II trial of imatinib in melanoma showed that patients with KIT amplification had lower disease control rate compared with patients carrying KIT mutations (18% amplified vs. 77% mutated)[90].

PALB2 Heterozygous deletion

Biological Impact

The partner and localizer of BRCA2 (PALB2) gene encodes a protein that plays a critical role in homologous recombination repair (HRR) through its ability to interact with BRCA2 in nuclear foci, promoting its localization and stability in key nuclear structures[104]. The Fanconi anemia complementation group (FANC) which includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2) are involved in the repair of DNA double-strand breaks (DSBs) by homologous recombination (HR)[105][106][107]. PALB2 is a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological function[108]. Biallelic germline loss-of-function mutations in PALB2 cause Fanconi anemia, whereas monoallelic loss-of-function mutations are associated with an increased risk of breast cancer and pancreatic cancer[109]. Fanconi Anemia is an autosomal recessive disease characterized by hematological abnormalities, bone marrow failure, limb deformities, skin hyperpigmentation, and susceptibility to hematologic and solid malignancies, such as acute myeloid leukemia and head and neck carcinoma[110][111].

Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate[112].

PALB2 loss of function mutation has been determined as an inclusion criterion for the trial evaluating rucaparib efficacy in ovarian cancer[113]or prostate cancer[114]; talazoparib efficacy in HER2-negative breast cancer (NCT02401347), prostate cancer (NCT03148795) or lung cancer (NCT03377556); niraparib efficacy in pancreatic cancer (NCT03553004), prostate cancer (NCT02854436), or any malignancy (except prostate) cancer (NCT03207347).

A case report demonstrated an exceptional response to mitomycin C and cisplatin treatment in a gemcitabine-resistant pancreatic cancer patient with biallelic inactivation of PALB2[115].

PDGFRA Amplification

Biological Impact

The PDGFRA gene encodes for the protein platelet-derived growth factor alpha (PDGFRA). The Ligand binding to the extracellular domain of PDGFRA induces receptor dimerization, enabling autophosphorylation of specific tyrosine residues and subsequently results in the activation of downstream pathways such as RAS-MAPK, PI3K and PLC-γ that are involved in developmental and cellular responses[116][117]. Mutations, insertions, deletions, fusions and genomic amplification of PDGFRA lead to its activation in several tumor types: ~7% of gastrointestinal stromal tumors (GISTs) have PDGFRA activating mutations and these mutations are mutually exclusive from KIT mutations[118]; activating mutations in PDGFRA have been observed in ~5% of Chinese melanoma patients[119]; amplification of PDGFRA is the second most frequent receptor tyrosine kinase amplification in glioblastoma (GBM)[120][121][122][17][123], intimal sarcomas[124], malignant peripheral nerve sheath tumors[125], non-small cell lung adenocarcinomas and non-small cell lung squamous cell carcinomas[126].

Therapeutic and prognostic relevance

A retrospective study showed that either KIT, PDGFRA, or EGFR amplification in glioma at the time of the first diagnosis was associated with an unfavorable overall survival[127].

In a preclinical study, a PDGFRA-amplified cell line was sensitive to imatinib, sunitinib and sorafenib treatment, demonstrated by disruption of downstream signaling and reduced cell viability in vitro[128]. Another study also showed that pazopanib could inhibit tumor growth in the PDGFRA-amplified pleomorphic liposarcoma xenograft mouse model[129].

ACT Onco® + Report

US FDA-APPROVED DRUG(S)

Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

- FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4[130] NCT01524783	**Lung or gastrointestinal neuroendocrine tumor** (Approved on 2016/02/26)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2[131] NCT00863655	**Breast cancer** (Approved on 2012/07/20)
	ER+/HER2-
	Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
EXIST-2 NCT00790400	**Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma** (Approved on 2012/04/26)
	-
	Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
RADIANT-3[132] NCT00510068	**Pancreatic neuroendocrine tumor** (Approved on 2011/05/05)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1[133] NCT00789828	**Subependymal giant cell astrocytoma** (Approved on 2010/10/29)
	-
	Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1[134] NCT00410124	**Renal cell carcinoma** (Approved on 2009/05/30)
	-
	Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

- FDA Approval Summary of Niraparib (ZEJULA)

PRIMA NCT02655016	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2020/04/29)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
QUADRA[135] NCT02354586	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2019/10/23)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)
	Niraparib [ORR(%): 24.0, DOR(M): 8.3]
NOVA[136] NCT01847274	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/03/27)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

ACT Onco® + Report

Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

- FDA Approval Summary of Olaparib (LYNPARZA)

OlympiA NCT02032823	**Her2-negative high-risk early breast cancer** (Approved on 2022/03/11)
	gBRCA
	Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M):]
PROfound[112] NCT02987543	**Prostate cancer** (Approved on 2020/05/19)
	ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1[137] NCT02477644	**Ovarian cancer** (Approved on 2020/05/08)
	HRD-positive (defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability)
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO[138] NCT02184195	**Pancreatic adenocarcinoma** (Approved on 2019/12/27)
	Germline BRCA mutation (deleterious/suspected deleterious)
	Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
SOLO-1[139] NCT01844986	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/12/19)
	Germline or somatic BRCA-mutated (gBRCAm or sBRCAm)
	Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
OlympiAD[140] NCT02000622	**Breast cancer** (Approved on 2018/02/06)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative
	Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
SOLO-2/ENGOT-Ov21[141] NCT01874353	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17)
	gBRCA+
	Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
Study19[142] NCT00753545	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2017/08/17)
	-
	Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]
Study 42[143] NCT01078662	**Ovarian cancer** (Approved on 2014/12/19)
	Germline BRCA mutation (deleterious/suspected deleterious)
	Olaparib [ORR(%): 34.0, DOR(M): 7.9]

Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

- FDA Approval Summary of Rucaparib (RUBRACA)

TRITON2 NCT02952534	**Prostate cancer** (Approved on 2020/05/15)
	gBRCA+, sBRCA
	Rucaparib [ORR(%): 44.0, DOR(M): NE]

ARIEL3[113] NCT01968213	**Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma** (Approved on 2018/04/06)
	All|HRD|tBRCA
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]
ARIEL2[144] NCT01482715, NCT01891344	**Ovarian cancer** (Approved on 2016/12/19)
	Germline and/or somatic BRCA mutation
	Rucaparib [ORR(%): 54.0]

Selumetinib (KOSELUGO)

Selumetinib is a kinase inhibitor. Selumetinib is developed and marketed by AstraZeneca under the trade name KOSELUGO.

- FDA Approval Summary of Selumetinib (KOSELUGO)

SPRINT NCT01362803	**Plexiform neurofibromas** (Approved on 2020/04/10)
	Neurofibromatosis type 1
	Selumetinib [ORR(%): 66.0]

Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

- FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA[145] NCT01945775	**Breast cancer** (Approved on 2018/10/16)
	Germline BRCA mutation (deleterious/suspected deleterious) HER2-negative
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

Trametinib (MEKINIST)

Trametinib is an anti-cancer inhibitor which targets MEK1 and MEK2. Trametinib is developed and marketed by GlaxoSmithKline (GSK) under the trade name MEKINIST.

- FDA Approval Summary of Trametinib (MEKINIST)

BRF117019, NCI-MATCH, CTMT212X2101 NCT02034110, NCT02465060, NCT02124772	**Cancer** (Approved on 2022/06/22)
	BRAF V600E
	Dabrafenib + trametinib [ORR(adult patients)(%): 41.0, ORR(pediatric patients)(%): 25.0]
BRF117019[146] NCT02034110	**Anaplastic thyroid cancer** (Approved on 2018/05/04)
	BRAF V600E
	Dabrafenib + trametinib [ORR(%): 61.0]
BRF113928[147] NCT01336634	**Non-small cell lung cancer** (Approved on 2017/06/22)
	BRAF V600E
	Trametinib + dabrafenib vs. Dabrafenib [ORR(%): 63.0 vs. 27.0, DOR(M): 12.6 vs. 9.9]

ACT Onco® + Report

COMBI-d[148] NCT01584648	**Melanoma** (Approved on 2014/01/10)
	BRAF V600E/K
	Trametinib + dabrafenib vs. Dabrafenib + placebo [PFS(M): 9.3 vs. 8.8]
METRIC[149] NCT01245062	**Melanoma** (Approved on 2013/05/29)
	BRAF V600E/K
	Trametinib vs. Dacarbazine or paclitaxel [PFS(M): 4.8 vs. 1.5]

D=day; W=week; M=month

ACT Onco® + Report

ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit https://clinicaltrials.gov to search and view for a complete list of open available and updated matched trials.

No trial has been found.

ACT Onco® + Report

SUPPLEMENTARY INFORMATION OF TESTING RESULTS

DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

- Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
NF1	Q83*	3	c.247C>T	NM_001042492	COSM6918545	96.1%	771

- Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



ACT Onco® + Report

OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ALK	V163L	1	c.487G>T	NM_004304	-	61.6%	615
APC	G857R	16	c.2569G>A	NM_000038	COSM2990997	31.5%	1348
ASXL1	R625Q	13	c.1874G>A	NM_015338	COSM8365891	5.8%	466
ERCC4	D562N	8	c.1684G>A	NM_005236	-	52.5%	2010
FANCD2	Splice region	-	c.1766+3A>G	NM_001018115	-	36.7%	1823
FGFR3	G65R	3	c.193G>A	NM_000142	-	93.9%	541
KMT2A	K269N	3	c.807G>T	NM_001197104	-	94.6%	1134
POLD1	D644E	16	c.1932C>G	NM_001256849	-	79.3%	720
PTCH1	A741V	14	c.2222C>T	NM_000264	-	53.0%	1925
RECQL4	R1021Q	19	c.3062G>A	NM_004260	COSM5062988	66.6%	736
RET	D1004H	18	c.3010G>C	NM_020975	-	9.1%	1260
RET	M1008I	18	c.3024G>A	NM_020975	-	9.1%	1258
RET	W988*	18	c.2964G>A	NM_020975	-	9.0%	1271
SMO	S590T	10	c.1769G>C	NM_005631	-	59.9%	2704
VEGFB	V150L	6	c.448G>C	NM_003377	-	47.9%	1882

Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

ACTOnco® + Report

TEST DETAILS

SPECIMEN RECEIVED AND PATHOLOGY REVIEW

- Collection date: Jul 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11125765L
- Collection site: Kindey
- Examined by: Dr. Chien-Ta Chiang
  1. The percentage of viable tumor cells in total cells in the whole slide (%): 25%
  2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 40%
  3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
  4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
  5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

RUN QC

- Panel: ACTOnco®+

DNA test

- Mean Depth: 1351x
- Target Base Coverage at 100x: 96%

RNA test

- Average unique RNA Start Sites per control GSP2: 136

LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

ACT Onco® + Report

NEXT-GENERATION SEQUENCING (NGS) METHODS

DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage ≥ 20, allele frequency ≥ 5% and actionable variants with allele frequency ≥ 2% were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at 100x ≥ 85% with a mean coverage ≥ 500x.

Variants reported in Genome Aggregation database with > 1% minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:
Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation ≥ 0.3 were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to ≥ 7.5 mutations per megabase (Muts/Mb); TMB-Low corresponds to < 7.5 Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is < 30%.

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in > 400 genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be ≥ 10.

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2 ≥ 3; (2) Number of supporting reads spanning the fusion junction ≥ 5; (3) Percentage of supporting reads spanning the fusion junction ≥ 10%; (4) Fusions annotated in Quiver Gene Fusion Database.

DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

Variant Analysis:
醫檢師陳韻伃 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

Sign Off
醫檢師陳韻伃 博士
Yun-Yu Chen Ph.D.
檢字第 015647 號

Yun Yu Chen

GENE LIST

SNV & CNV

*ABCB1**	*ABCC2**	*ABCG2**	*ABL1*	*ABL2*	*ADAMTS1*	*ADAMTS13*	*ADAMTS15*	*ADAMTS16*	*ADAMTS18*	*ADAMTS6*	*ADAMTS9*
ADAMTSL1	*ADGRA2*	*ADH1C**	*AKT1*	*AKT2*	*AKT3*	*ALDH1A1**	*ALK*	*AMER1*	*APC*	*AR*	*ARAF*
ARID1A	*ARID1B*	*ARID2*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*	*AURKB*	*AXIN1*	*AXIN2*	*AXL*
B2M	*BAP1*	*BARD1*	*BCL10*	*BCL2**	*BCL2L1*	*BCL2L2**	*BCL6*	*BCL9*	*BCOR*	*BIRC2*	*BIRC3*
BLM	*BMPR1A*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2**	*BTK*	*BUB1B*	*CALR*
CANX	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCNA1*	*CCNA*	*CCNB1*	*CCNB2*	*CCNB3*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CCNE2*	*CCNH*	*CD19*	*CD274*	*CD58*	*CD70**	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK1	*CDK12*	*CDK2*	*CDK4*	*CDK5*	*CDK6*	*CDK7*	*CDK8*	*CDK9*	*CDKN1A*	*CDKN1B*	*CDKN2A*
CDKN2B	*CDKN2C*	*CEBPA**	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CRLF2*	*CSF1R*	*CTCF*	*CTLA4*
CTNNA1	*CTNNB1*	*CUL3*	*CYLD*	*CYP1A1**	*CYP2B6**	*CYP2C19**	*CYP2C8**	*CYP2D6*	*CYP2E1**	*CYP3A4**	*CYP3A5**
DAXX	*DCUN1D1*	*DDR2*	*DICER1*	*DNMT3A*	*DOT1L*	*DPYD*	*DTX1*	*E2F3*	*EGFR*	*EP300*	*EPCAM*
EPHA2	*EPHA3*	*EPHA5*	*EPHA7*	*EPHB1*	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC1*	*ERCC2*	*ERCC3*	*ERCC4*
ERCC5	*ERG*	*ESR1*	*ESR2*	*ETV1*	*ETV4*	*EZH2*	*FAM46C*	*FANCA*	*FANCC*	*FANCD2*	*FANCE*
FANCF	*FANCG*	*FANCL*	*FAS*	*FAT1*	*FBXW7*	*FCGR2B*	*FGF1**	*FGF10*	*FGF14*	*FGF19**	*FGF23*
FGF3	*FGF4**	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*	*FH*	*FLCN*	*FLT1*	*FLT3*	*FLT4*
*FOXL2**	*FOXP1*	*FRG1*	*FUBP1*	*GATA1*	*GATA2*	*GATA3*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GREM1*
GRIN2A	*GSK3B*	*GSTP1**	*GSTT1**	*HGF*	*HIF1A*	*HIST1H1C**	*HIST1H1E**	*HNF1A*	*HR*	*HRAS**	*HSP90AA1*
HSP90AB1	*HSPA4*	*HSPA5*	*IDH1*	*IDH2*	*IFNL3**	*IGF1*	*IGF1R*	*IGF2*	*IKBKB*	*IKBKE*	*IKZF1*
IL6	*IL7R*	*INPP4B*	*INSR*	*IRF4*	*IRS1*	*IRS2**	*JAK1*	*JAK2*	*JAK3*	*JUN**	*KAT6A*
KDM5A	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KIT*	*KMT2A*	*KMT2C*	*KMT2D*	*KRAS*	*LCK*	*LIG1*
LIG3	*LMO1*	*LRP1B*	*LYN*	*MALT1*	*MAP2K1*	*MAP2K2*	*MAP2K4*	*MAP3K1*	*MAP3K7*	*MAPK1*	*MAPK3*
MAX	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MET*	*MITF*	*MLH1*	*MPL*	*MRE11*
MSH2	*MSH6*	*MTHFR**	*MTOR*	*MUC16*	*MUC4*	*MUC6*	*MUTYH*	*MYC*	*MYCL*	*MYCN*	*MYD88*
*NAT2**	*NBN*	*NEFH*	*NF1*	*NF2*	*NFE2L2*	*NFKB1*	*NFKBIA*	*NKX2-1**	*NOTCH1*	*NOTCH2*	*NOTCH3*
NOTCH4	*NPM1*	*NQO1**	*NRAS*	*NSD1*	*NTRK1*	*NTRK2*	*NTRK3*	*PAK3*	*PALB2*	*PARP1*	*PAX5*
PAX8	*PBRM1*	*PDCD1*	*PDCD1LG2*	*PDGFRA*	*PDGFRB*	*PDIA3*	*PGF*	*PHOX2B**	*PIK3C2B*	*PIK3C2G*	*PIK3C3*
PIK3CA	*PIK3CB*	*PIK3CD*	*PIK3CG*	*PIK3R1*	*PIK3R2*	*PIK3R3*	*PIM1*	*PMS1*	*PMS2*	*POLB*	*POLD1*
POLE	*PPARG*	*PPP2R1A*	*PRDM1*	*PRKAR1A*	*PRKCA*	*PRKCB*	*PRKCG*	*PRKCI*	*PRKCQ*	*PRKDC*	*PRKN*
PSMB8	*PSMB9*	*PSME1*	*PSME2*	*PSME3*	*PTCH1*	*PTEN*	*PTGS2*	*PTPN11*	*PTPRD*	*PTPRT*	*RAC1*
RAD50	*RAD51*	*RAD51B*	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*RECQL4*
REL	*RET*	*RHOA*	*RICTOR*	*RNF43*	*ROS1*	*RPPH1*	*RPTOR*	*RUNX1*	*RUNX1T1*	*RXRA*	*SDHA*
SDHB	*SDHC*	*SDHD*	*SERPINB3*	*SERPINB4*	*SETD2*	*SF3B1*	*SGK1*	*SH2D1A**	*SLC19A1**	*SLC22A2**	*SLCO1B1**
*SLCO1B3**	*SMAD2*	*SMAD3*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SOCS1**	*SOX2**	*SOX9*	*SPEN*	*SPOP*
SRC	*STAG2*	*STAT3*	*STK11*	*SUFU*	*SYK*	*SYNE1*	*TAF1*	*TAP1*	*TAP2*	*TAPBP*	*TBX3*
TEK	*TERT*	*TET1*	*TET2*	*TGFBR2*	*TMSB4X**	*TNF*	*TNFAIP3*	*TNFRSF14*	*TNFSF11*	*TOP1*	*TP53*
*TPMT**	*TSC1*	*TSC2*	*TSHR*	*TYMS*	*U2AF1*	*UBE2A**	*UBE2K*	*UBR5*	*UGT1A1**	*USH2A*	*VDR**
VEGFA	*VEGFB*	*VHL*	*WT1*	*XIAP*	*XPO1*	*XRCC2*	*ZNF217*				

*Analysis of copy number alterations NOT available.

FUSION

ALK	*BRAF*	*EGFR*	*FGFR1*	*FGFR2*	*FGFR3*	*MET*	*NRG1*	*NTRK1*	*NTRK2*	*NTRK3*	*RET*	*ROS1*

ACT Onco® + Report

APPENDIX

POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
PALB2	Niraparib, Olaparib, Rucaparib, Talazoparib	**sensitive**

SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Olaparib, Niraparib, Rucaparib, Talazoparib



1: Everolimus; 2: Trametinib, Selumetinib

ACT Onco® + Report

DISCLAIMER

法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。
本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。
本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

ACT Onco® + Report

REFERENCE

1. PMID: 8563751; 1996, Nat Genet;12(2):144-8
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

2. PMID: 1946382; 1991, Proc Natl Acad Sci U S A;88(21):9658-62
Identification of the neurofibromatosis type 1 gene product.

3. PMID: 2116237; 1990, Cell;62(3):599-608
The neurofibromatosis type 1 gene encodes a protein related to GAP.

4. PMID: 2121370; 1990, Cell;63(4):843-9
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.

5. PMID: 14502561; 2003, J Cell Physiol;197(2):214-24
NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.

6. PMID: 19479903; 2009, Mol Carcinog;48(11):1005-17
Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase.

7. PMID: 28680740; 2017, Adv Med Biol;118():83-122
Haploinsufficient tumor suppressor genes.

8. PMID: 10442636; 1999, Oncogene;18(31):4450-9
Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation.

9. PMID: 16288202; 2006, Oncogene;25(16):2297-303
Nf1 haploinsufficiency augments angiogenesis.

10. PMID: 18089636; 2008, Hum Mol Genet;17(7):936-48
Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.

11. PMID: 7920653; 1994, Nat Genet;7(3):353-61
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

12. PMID: 25026295; 2014, Oncotarget;5(15):5873-92
The NF1 gene revisited - from bench to bedside.

13. PMID: 29892687; 2018, Gynecol Oncol Rep;23():41-44
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.

14. PMID: 29926297; 2018, Breast Cancer Res Treat;171(3):719-735
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.

15. PMID: 28637487; 2017, Hum Genomics;11(1):13
The NF1 somatic mutational landscape in sporadic human cancers.

16. PMID: 15840687; 2005, Gut;54(8):1129-35
NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.

17. PMID: 20129251; 2010, Cancer Cell;17(1):98-110
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

18. PMID: 27158780; 2016, Nat Genet;48(6):607-16
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.

19. PMID: 32669708; 2020, Nature;583(7818):807-812

The National Lung Matrix Trial of personalized therapy in lung cancer.

20. PMID: 21482774; 2012, Proc Natl Acad Sci U S A;109(8):2730-5
Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.

21. PMID: 24535670; 2014, Cancer Discov;4(5):606-19
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

22. PMID: 29703253; 2018, BMC Cancer;18(1):479
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.

23. PMID: 30858928; 2019, Oncotarget;10(14):1440-1457
CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition.

24. PMID: 24576830; 2014, Cancer Res;74(8):2340-50
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

25. PMID: 23171796; 2013, Cancer Discov;3(3):338-49
Elucidating distinct roles for NF1 in melanomagenesis.

26. PMID: 23288408; 2013, Cancer Discov;3(3):350-62
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

27. PMID: 24265153; 2014, Cancer Discov;4(1):94-109
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

28. PMID: 30269082; 2019, Gut;68(7):1152-1161
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.

29. PMID: 26936308; 2016, J Clin Pharm Ther;41(3):357-359
Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.

30. PMID: 22573716; 2012, Cancer Res;72(13):3350-9
Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.

31. PMID: 19727076; 2009, Nature;461(7262):411-4
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

32. PMID: 23858101; 2013, Mol Cancer Ther;12(9):1906-17
NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.

33. PMID: 23221341; 2013, J Clin Invest;123(1):340-7
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

34. PMID: 18483311; 2008, Mol Cancer Ther;7(5):1237-45
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

35. PMID: 23209032; 2013, Clin Cancer Res;19(2):450-61
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

36. PMID: 26859683; 2016, Oncotarget;7(9):10547-56
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

37. PMID: 11278692; 2001, J Biol Chem;276(15):11877-82
CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.

38. PMID: 26260210; 2015, Mol Immunol;68(2 Pt C):546-57

TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex.

39. PMID: 18323416; 2008, Science;319(5870):1676-9
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

40. PMID: 26212909; 2015, Am J Pathol;185(9):2354-63
Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation.

41. PMID: 22397314; 2012, Leuk Lymphoma;53(10):1971-7
Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.

42. PMID: 26668357; 2015, Proc Natl Acad Sci U S A;112(52):E7230-8
Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.

43. PMID: 26876250; 2016, Zhonghua Xue Ye Xue Za Zhi;37(1):30-4
[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma].

44. PMID: 18045542; 2007, Cell;131(5):1018
SnapShot: EGFR signaling pathway.

45. PMID: 10880430; 2000, EMBO J;19(13):3159-67
The ErbB signaling network: receptor heterodimerization in development and cancer.

46. PMID: 15329413; 2004, Proc Natl Acad Sci U S A;101(36):13306-11
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

47. PMID: 11426640; 2000, Oncogene;19(56):6550-65
The EGF receptor family as targets for cancer therapy.

48. PMID: 28351930; 2017, Clin Cancer Res;23(15):4242-4250
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

49. PMID: 17664472; 2007, J Clin Oncol;25(22):3238-45
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

50. PMID: 22152101; 2011, BMC Cancer;11():509
Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

51. PMID: 24141978; 2013, Sci Rep;3():2992
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.

52. PMID: 29158193; 2018, J Thorac Oncol;13(2):228-236
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

53. PMID: 19102716; 2009, Pharmacogenomics;10(1):59-68
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.

54. PMID: 15870435; 2005, J Natl Cancer Inst;97(9):643-55
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

55. PMID: 15998906; 2005, J Clin Oncol;23(28):6838-45
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

56. PMID: 16204011; 2005, J Clin Oncol;23(31):8081-92
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

57. PMID: 23557218; 2013, J Transl Med;11():90
High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.

58. PMID: 26141217; 2015, Lung Cancer;89(3):337-42
Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.

59. PMID: 28537764; 2017, J Clin Oncol;35(20):2279-2287
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.

60. PMID: 28057415; 2017, Clin Genitourin Cancer;15(4):e727-e734
Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

61. PMID: 30463996; 2019, Cancer Discov;9(2):199-209
EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

62. PMID: 28575464; 2017, Neuro Oncol;19(11):1522-1531
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.

63. PMID: 9237710; 1997, J Infect Dis;176(2):439-44
Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia.

64. PMID: 14581334; 2003, Clin Cancer Res;9(13):4653-65
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

65. PMID: 16199153; 2005, Eur J Cancer;41(16):2502-12
The role of IL-6 and STAT3 in inflammation and cancer.

66. PMID: 28778705; 2017, Autoimmun Rev;16(10):1079-1089
Targeting interleukin-6 in autoimmune uveitis.

67. PMID: 21220315; 2011, Proc Natl Acad Sci U S A;108(4):1397-402
Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.

68. PMID: 20713723; 2010, Proc Natl Acad Sci U S A;107(35):15535-40
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

69. PMID: 24644001; 2014, Clin Cancer Res;20(10):2714-26
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.

70. PMID: 22819326; 2012, Mol Cell;47(4):570-84
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.

71. PMID: 17224923; 2007, Br J Cancer;96(3):474-6
Interleukin-6 gene amplification and shortened survival in glioblastoma patients.

72. PMID: 23172303; 2013, J Biochem;153(1):13-9
Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.

73. PMID: 12778165; 2003, Nat Med;9(6):669-76
The biology of VEGF and its receptors.

74. PMID: 21382095; 2011, Neuropathology;31(6):583-8
Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.

75. PMID: 31604903; 2020, Oncologist;25(1):e39-e47
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

76. PMID: 23028128; 2012, Cold Spring Harb Perspect Med;2(10):

Anti-VEGF therapies in the clinic.

77. PMID: 27718781; 2016, N Engl J Med;375(23):2246-2254
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

78. PMID: 29972759; 2018, N Engl J Med;379(1):54-63
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

79. PMID: 27160228; 2016, J Natl Compr Canc Netw;14(5):499-502
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.

80. PMID: 25639617; 2015, Breast J;21(2):205-7
Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.

81. PMID: 26578684; 2016, Clin Cancer Res;22(8):1940-50
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.

82. PMID: 29855279; 2018, BMC Cancer;18(1):618
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report.

83. PMID: 31786466; 2020, Biomed Pharmacother;122():109587
Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.

84. PMID: 22170730; 2012, Genes Chromosomes Cancer;51(4):375-83
Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis.

85. PMID: 17546049; 2007, Oncogene;26(54):7560-8
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.

86. PMID: 15365079; 2004, J Clin Oncol;22(18):3813-25
Biology of gastrointestinal stromal tumors.

87. PMID: 22089421; 2011, Nat Rev Cancer;11(12):865-78
Gastrointestinal stromal tumours: origin and molecular oncology.

88. PMID: 21690468; 2011, J Clin Oncol;29(21):2904-9
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

89. PMID: 21642685; 2011, JAMA;305(22):2327-34
KIT as a therapeutic target in metastatic melanoma.

90. PMID: 23775962; 2013, J Clin Oncol;31(26):3182-90
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

91. PMID: 12181401; 2002, N Engl J Med;347(7):472-80
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

92. PMID: 18955458; 2008, J Clin Oncol;26(33):5352-9
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

93. PMID: 19164557; 2009, Proc Natl Acad Sci U S A;106(5):1542-7
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

94. PMID: 18235121; 2008, J Clin Oncol;26(4):620-5
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

95. PMID: 16098458; 2005, Eur J Cancer;41(12):1751-7
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

96. PMID: 15451219; 2004, Lancet;364(9440):1127-34
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

97. PMID: 23177515; 2013, Lancet;381(9863):295-302
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

98. PMID: 25641662; 2015, Cancer;121(9):1405-13
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.

99. PMID: 19282169; 2009, Eur J Cancer;45(11):1959-68
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

100. PMID: 32511981; 2020, Lancet Oncol;21(7):923-934
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

101. PMID: 28327988; 2017, Ann Oncol;28(6):1380-1387
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

102. PMID: 15583695; 2004, Br J Cancer;91(12):2048-55
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.

103. PMID: 32350132; 2020, Sci Transl Med;12(541):
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.

104. PMID: 16793542; 2006, Mol Cell;22(6):719-29
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

105. PMID: 23325218; 2013, Nature;493(7432):356-63
Fanconi anaemia and the repair of Watson and Crick DNA crosslinks.

106. PMID: 15905196; 2005, Carcinogenesis;26(10):1731-40
The Fanconi anemia group A protein modulates homologous repair of DNA double-strand breaks in mammalian cells.

107. PMID: 27037238; 2016, EMBO J;35(9):909-23
Interplay between Fanconi anemia and homologous recombination pathways in genome integrity.

108. PMID: 24153426; 2013, Nat Commun;4():2578
Heterozygous mutations in PALB2 cause DNA replication and damage response defects.

109. PMID: 20858716; 2010, Cancer Res;70(19):7353-9
PALB2/FANCN: recombining cancer and Fanconi anemia.

110. PMID: 25754594; 2015, Hum Mutat;36(5):562-8
Loss-of-Function FANCL Mutations Associate with Severe Fanconi Anemia Overlapping the VACTERL Association.

111. PMID: 28678401; 2017, Cancer;123(20):3943-3954
Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.

112. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102
Olaparib for Metastatic Castration-Resistant Prostate Cancer.

113. PMID: 28916367; 2017, Lancet;390(10106):1949-1961
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind,

placebo-controlled, phase 3 trial.

114. PMID: 32086346; 2020, Clin Cancer Res;26(11):2487-2496
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

115. PMID: 21135251; 2011, Mol Cancer Ther;10(1):3-8
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

116. PMID: 18483217; 2008, Genes Dev;22(10):1276-312
Role of platelet-derived growth factors in physiology and medicine.

117. PMID: 3013421; 1986, Cell;46(2):155-69
The biology of platelet-derived growth factor.

118. PMID: 20023271; 2010, Am J Clin Pathol;133(1):149-55
Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort.

119. PMID: 24132921; 2013, Clin Cancer Res;19(24):6935-42
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

120. PMID: 18772890; 2008, Nature;455(7216):1061-8
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

121. PMID: 19915670; 2009, PLoS One;4(11):e7752
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.

122. PMID: 22323597; 2012, Proc Natl Acad Sci U S A;109(8):3041-6
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.

123. PMID: 20889717; 2010, Genes Dev;24(19):2205-18
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

124. PMID: 20685895; 2010, Cancer Res;70(18):7304-14
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.

125. PMID: 16357008; 2006, Carcinogenesis;27(3):664-71
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.

126. PMID: 19755855; 2009, Cancer Biol Ther;8(21):2042-50
Amplification of chromosomal segment 4q12 in non-small cell lung cancer.

127. PMID: 17189383; 2006, Mol Cancer Res;4(12):927-34
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.

128. PMID: 19366796; 2009, Cancer Res;69(9):3937-46
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

129. PMID: 30060824; 2018, Tissue Cell;53():30-36
Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model.

130. PMID: 26703889; 2016, Lancet;387(10022):968-977
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a

randomised, placebo-controlled, phase 3 study.

131. PMID: 22149876; 2012, N Engl J Med;366(6):520-9
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

132. PMID: 21306238; 2011, N Engl J Med;364(6):514-23
Everolimus for advanced pancreatic neuroendocrine tumors.

133. PMID: 23158522; 2013, Lancet;381(9861):125-32
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

134. PMID: 18653228; 2008, Lancet;372(9637):449-56
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

135. PMID: 30948273; 2019, Lancet Oncol;20(5):636-648
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

136. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

137. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

138. PMID: 31157963; 2019, N Engl J Med;381(4):317-327
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

139. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

140. PMID: 28578601; 2017, N Engl J Med;377(6):523-533
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

141. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

142. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

143. PMID: 25366685; 2015, J Clin Oncol;33(3):244-50
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

144. PMID: 27908594; 2017, Lancet Oncol;18(1):75-87
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

145. PMID: 30110579; 2018, N Engl J Med;379(8):753-763
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

146. PMID: 29072975; 2018, J Clin Oncol;36(1):7-13
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

147. PMID: 27080216; 2016, Lancet Oncol;17(5):642-50
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

148. PMID: 25265492; 2014, N Engl J Med;371(20):1877-88
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

ACT Onco® + Report

149. PMID: 22663011; 2012, N Engl J Med;367(2):107-14
Improved survival with MEK inhibition in BRAF-mutated melanoma.